Adaptimmune Therapeutics plc (ADAP) Reaches $8.45 After 9.00% Up Move; Quinn Opportunity Partners Upped Its Genworth Financial (GNW) Position

February 15, 2018 - By Michael Collier

Quinn Opportunity Partners Llc increased Genworth Financial Inc (GNW) stake by 61.38% reported in 2017Q3 SEC filing. Quinn Opportunity Partners Llc acquired 350,787 shares as Genworth Financial Inc (GNW)’s stock declined 8.54%. The Quinn Opportunity Partners Llc holds 922,293 shares with $3.55 million value, up from 571,506 last quarter. Genworth Financial Inc now has $1.43 billion valuation. It closed at $2.87 lastly. It is down 3.41% since February 15, 2017 and is uptrending. It has underperformed by 13.29% the S&P500.

The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a huge mover today! The stock increased 2.67% or $0.22 during the last trading session, reaching $8.45. About 223,091 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since February 15, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.The move comes after 7 months positive chart setup for the $791.65M company. It was reported on Feb, 15 by We have $9.21 PT which if reached, will make NASDAQ:ADAP worth $71.25M more.

Among 5 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Adaptimmune Therapeutics PLC had 5 analyst reports since February 25, 2016 according to SRatingsIntel. Bank of America downgraded the stock to “Underperform” rating in Monday, October 24 report. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) has “Buy” rating given on Tuesday, June 6 by Cowen & Co. The rating was initiated by Citigroup with “Buy” on Thursday, February 25. The rating was maintained by SunTrust with “Buy” on Saturday, November 11.

Analysts await Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report earnings on March, 12. They expect $-0.25 earnings per share, down 13.64% or $0.03 from last year’s $-0.22 per share.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $791.65 million. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Investors sentiment increased to 1.28 in Q3 2017. Its up 0.13, from 1.15 in 2017Q2. It improved, as 17 investors sold GNW shares while 77 reduced holdings. 44 funds opened positions while 76 raised stakes. 315.12 million shares or 4.07% less from 328.49 million shares in 2017Q2 were reported. 117,000 were reported by Creative Planning. Mason Street Advsr Limited Liability Com holds 0.02% or 247,743 shares in its portfolio. Ls Advsrs Ltd has 0.01% invested in Genworth Financial, Inc. (NYSE:GNW) for 39,816 shares. Gam Ag has invested 0.02% of its portfolio in Genworth Financial, Inc. (NYSE:GNW). Cubist Systematic Strategies Lc reported 31,778 shares. Cutler Capital Mgmt Llc invested 0.27% in Genworth Financial, Inc. (NYSE:GNW). Adirondack Rech Mngmt holds 1.57% of its portfolio in Genworth Financial, Inc. (NYSE:GNW) for 1.04M shares. Blackrock has invested 0.01% in Genworth Financial, Inc. (NYSE:GNW). Moreover, Old Mutual Customised Solutions (Proprietary) Ltd has 0.03% invested in Genworth Financial, Inc. (NYSE:GNW) for 48,000 shares. Taconic Advisors Limited Partnership reported 1.00M shares. Eqis Capital Mngmt Incorporated invested 0.61% of its portfolio in Genworth Financial, Inc. (NYSE:GNW). Davidson Garrard invested in 0.02% or 18,371 shares. State Treasurer State Of Michigan invested in 0.01% or 187,750 shares. Voya Mngmt Limited Co reported 0% of its portfolio in Genworth Financial, Inc. (NYSE:GNW). First Wilshire Securities Mngmt has 0.9% invested in Genworth Financial, Inc. (NYSE:GNW) for 821,578 shares.

Among 8 analysts covering Genworth Financial (NYSE:GNW), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. Genworth Financial had 22 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “” rating on Wednesday, September 2 by Wood. The company was initiated on Tuesday, November 17 by Goldman Sachs. The firm earned “Neutral” rating on Wednesday, August 5 by Macquarie Research. As per Tuesday, August 1, the company rating was maintained by Wells Fargo. BTIG Research downgraded Genworth Financial, Inc. (NYSE:GNW) on Wednesday, October 5 to “Neutral” rating. The firm earned “Market Perform” rating on Friday, September 23 by Wells Fargo. The company was downgraded on Wednesday, November 4 by UBS. The firm has “Buy” rating by Compass Point given on Friday, November 11. The firm has “Neutral” rating given on Monday, September 19 by Compass Point. The firm earned “Buy” rating on Monday, February 8 by Compass Point.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: